

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virgina 22313-1450 www.spile.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/990,909	11/16/2001	Joan M. Fallon	25324-0021001	3427
26191 FISH & RICH	7590 08/20/2019 ARDSON P.C.	EXAMINER		
PO BOX 1022			LUCAS, ZACHARIAH	
MINNEAPOL	IS, MN 55440-1022		ART UNIT	PAPER NUMBER
			1648	
			NOTIFICATION DATE	DELIVERY MODE
			08/20/2010	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PATDOCTC@fr.com

Notice of Non-Compliant Amendment (37 CFR 1.121)

Application No.	Applicant(s)			
09/990,909	FALLON, JOAN	M.		
Examiner	Art Unit			
ZACHADIAH LUCAS	16/18			

The MAILING DATE of this communication appear	ars on the cover sheet with the correspondence address
	on-compliant because it has failed to meet the requirements of nt to be compliant, correction of the following item(s) is required
THE FOLLOWING MARKED (X) ITEM(S) CAUSE THE AT 1. Amendments to the specification: A. Amended paragraph(s) do not include m B. New paragraph(s) should not be underlii C. Other	narkings.
2. Abstract: A. Not presented on a separate sheet. 37 C B. Other	DFR 1.72.
"Annotated Sheet" as required by 37 CF B. The practice of submitting proposed dra	in the top margin as "Replacement Sheet," "New Sheet," or "R 1.121(d). wing correction has been eliminated. Replacement drawings ings, in compliance with 37 CFR 1.84 are required.
C. Each claim has not been provided with to f each claim cannot be identified. Note number by using one of the following sta (Previously presented), (New), (Not ente	not present. a text of all pending claims (including withdrawn claims) he proper status identifier, and as such, the individual status be: the status of every claim must be indicated after its claim stus identifiers (Original), (Currently amended), (Canceled), ared), (Withdrawn) and (Withdrawn-currently amended). ve not been presented in ascending numerical order.
5. Other (e.g., the amendment is unsigned or not	signed in accordance with 37 CFR 1.4):
For further explanation of the amendment format required	by 37 CFR 1.121, see MPEP § 714.
TIME PERIODS FOR FILING A REPLY TO THIS NOTICE	: :
	pliant amendment is an after-final amendment or an amendmer he non-compliant after-final amendment with corrections, the
correction, if the non-compliant amendment is one of t (including a submission for a request for continued ex- amendment filed within a suspension period under 37	chever is longer, from the mail date of this notice to supply the he following: a preliminary amendment, a non-final amendment aminiation (RCE) under 37 CFR 1.114), a supplemental CFR 1.103(a) or (c), and an amendment filed in response to a ked, the correction required is only the corrected section of the 1.1.21.
Extensions of time are available under 37 CFR 1. amendment or an amendment filed in response to a	136(a) <u>only</u> if the non-compliant amendment is a non-final a <i>Quayle</i> action.
filed in response to a Quayle action; or	in: pliant amendment is a non-final amendment or an amendment int amendment is a preliminary amendment or supplemental
	/Zachariah Lucas/ Primary Examiner, Art Unit 1648

U.S. Patent and Trademark Office

PTOL-324 (01-06)

Continuation Sheet (PTOL-324) Application No. 09/990,909

Continuation of 4(e) Other: Claims 30-35, 39-44, and 50-55 should be identified as (Withdrawn-currently amended).

The presented claims do not show the changes being made to the claims relative to the immediately prior version of the claims-those submitted to the Office on November 13, 2009, See e.g. the analyzing step of claim 1, which fails to indicate what became of the "or absence" langauge inserted into the claim or the "one or more" inserted before the term antigens preceding the term "assocaited" in the claim in the November 2009 amendment.